78 related articles for article (PubMed ID: 2140863)
1. Ocular toxic effects of fenretinide.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
J Natl Cancer Inst; 1990 Jun; 82(12):1063. PubMed ID: 2140863
[No Abstract] [Full Text] [Related]
2. Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl) retinamide therapy for psoriasis.
Kingston TP; Lowe NJ; Winston J; Heckenlively J
Clin Exp Dermatol; 1986 Nov; 11(6):624-7. PubMed ID: 2959409
[No Abstract] [Full Text] [Related]
3. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
4. Abnormal retinal function associated with fenretinide, a synthetic retinoid.
Kaiser-Kupfer MI; Peck GL; Caruso RC; Jaffe MJ; DiGiovanna JJ; Gross EG
Arch Ophthalmol; 1986 Jan; 104(1):69-70. PubMed ID: 2935125
[TBL] [Abstract][Full Text] [Related]
5. Ocular side effects of isotretinoin therapy.
Caffery BE; Josephson JE
J Am Optom Assoc; 1988 Mar; 59(3):221-4. PubMed ID: 3258326
[TBL] [Abstract][Full Text] [Related]
6. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
[TBL] [Abstract][Full Text] [Related]
7. The synthetic retinoid fenretinide does not affect circulating hormone concentrations.
Secreto G; Costa A; Recchiane C; Pizzichetta M; Ballerini P
Breast Cancer Res Treat; 1988 Dec; 12(3):315-6. PubMed ID: 2976280
[No Abstract] [Full Text] [Related]
8. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
9. Chronic oral administration of fenretinide, as a chemopreventive agent to breast cancer patients, does not affect plasma alpha-tocopherol concentration.
Formelli F; Clerici M; De Palo G; Costa A; Veronesi U
Ann Oncol; 1991 Jun; 2(6):446-7. PubMed ID: 1837481
[No Abstract] [Full Text] [Related]
10. Retinoids and the eye.
Gross EG; Helfgott MA
Dermatol Clin; 1992 Jul; 10(3):521-31. PubMed ID: 1617811
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of fenretinide-induced apoptosis.
Hail N; Kim HJ; Lotan R
Apoptosis; 2006 Oct; 11(10):1677-94. PubMed ID: 16850162
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
13. The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.
Torrisi R; Pensa F; Fontana V; Costa A; Decensi A
Eur J Cancer; 1995; 31A(3):420-1. PubMed ID: 7786612
[No Abstract] [Full Text] [Related]
14. High-performance liquid chromatographic analysis of fenretinide in rodent feed.
Schrader PA; Sisco WR
J Chromatogr; 1987 Nov; 408():430-4. PubMed ID: 2963013
[No Abstract] [Full Text] [Related]
15. Stability-indicating reversed-phase high-performance liquid chromatographic assay for fenretinide drug substance.
Sisco WR; DiFeo TJ
J Chromatogr; 1985 Apr; 322(2):380-5. PubMed ID: 3158667
[No Abstract] [Full Text] [Related]
16. Stability-indicating reversed-phase high-performance liquid chromatographic assay for fenretinide in soft gelatin capsules and concentrated corn oil suspensions.
Sisco WR; Schrader PA; McLaughlin AM; Clark BH
J Chromatogr; 1986 Oct; 368(1):184-7. PubMed ID: 2946708
[No Abstract] [Full Text] [Related]
17. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
18. Night vision in the miotic eye.
Stewart WC; Madill HD; Dyer AM
Can Med Assoc J; 1968 Dec; 99(23):1145-8. PubMed ID: 5303617
[No Abstract] [Full Text] [Related]
19. Functional abnormalities in vincristine-induced night blindness.
Ripps H; Carr RE; Siegel IM; Greenstein VC
Invest Ophthalmol Vis Sci; 1984 Jul; 25(7):787-94. PubMed ID: 6329990
[TBL] [Abstract][Full Text] [Related]
20. ELECTROPHYSIOLOGIC ASPECTS OF SEVERAL RETINAL DISEASES.
CARR RE; SIEGEL IM
Am J Ophthalmol; 1964 Jul; 58():95-107. PubMed ID: 14177989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
